Zacks' 7 Best Stocks for May, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/17/2013

Company Name Symbol %Change
VIASAT INC VSAT
19.35%
OLD SECOND B OSBC
5.76%
GAMCO INVEST GBL
4.61%
CORNING INC GLW
4.47%
SYNCHRONOSS SNCR
4.23%

Rite Aid Posts Strong April Comps

by Zacks Equity Research

May 08, 2012 | Comments : 0 Recommended this article: (2)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Drugstore chain Rite Aid Corporation’s ( RAD - Analyst Report ) same-store sales (comps) for the one month ended April 28, 2012, rose 2.9%, based on strong front-end, pharmacy and prescription count comps for the month. Front-end same-store sales for April 2012 increased 2.7%, while pharmacy and prescription count comps were up 3.0% and 3.8%, respectively.

Pharmacy comps for April included a negative impact of around 311 basis points from new generic introductions.

Rite Aid reported total drugstore sales of $1.993 billion in April, with prescription sales accounting for 67.9% of drugstore sales and third party prescription sales making up for 96.6% of pharmacy sales. The company’s April sales represented a 2.5% rise from the year-ago level of $1.945 billion.

Comps so far in fiscal 2012

Year-to-date, Rite Aid has registered a comps increase of 3.3% for the eight weeks ended April 28, 2012. Comps for the period comprised 3.6% front-end comps, 3.1% pharmacy comps and 3.2% prescription comps.

Net sales of $3.982 billion, thus far, in fiscal 2012 represent a 2.8% increase from $3.875 billion reported in the year-ago period. Sales for the eight-week period included 68.5% contribution from prescription sales and 96.7% from pharmacy sales.

Our Take

In an effort to expand its pharmacy and clinical services, Rite Aid has applied additional resources, such as Wellness+ program for diabetes and Flu Immunization program. We believe these programs will enable the company to increase its customer base as well as long-term profitability.

Moreover, the company is in the process of various cost cutting initiatives including centralized indirect procurement of drugs, administrative headcounts requirement, reducing supply chain costs, reducing debt, etc. which will certainly benefit the company to improve its bottom line.

Headquartered in Camp Hill, Pennsylvania, Rite Aid is the third largest retail drugstore in the U.S. based on revenues and number of stores. The company operates in 31 states across the country and in the District of Columbia. As of April 28, 2012, the company operated 4,658 stores versus 4,705 stores in the same period last year.

Rite Aid, which competes with CVS Caremark Corporation ( CVS - Analyst Report ) and Walgreen Co. ( WAG - Analyst Report ) , currently, holds a Zacks #2 Rank, implying a short-term ‘Buy’ rating on the stock. The company retains a long-term ‘Neutral’ recommendation on the stock.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (2)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.